Pyxis Oncology, Inc.近日发布了其2026年第一季度的财务业绩,并同步宣布正积极推进其重点候选药物Micvo,旨在实现2026年设定的关键临床开发目标。
公司本季度的财务数据为后续研发投入提供了支撑。与此同时,针对Micvo的临床开发计划取得了显著进展,各项准备工作正按既定时间表向前推进,为达成年度重要临床里程碑奠定了坚实基础。
Pyxis Oncology, Inc.近日发布了其2026年第一季度的财务业绩,并同步宣布正积极推进其重点候选药物Micvo,旨在实现2026年设定的关键临床开发目标。
公司本季度的财务数据为后续研发投入提供了支撑。与此同时,针对Micvo的临床开发计划取得了显著进展,各项准备工作正按既定时间表向前推进,为达成年度重要临床里程碑奠定了坚实基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.